Why Catalent Inc. Rose as Much as 17% This Morning
Shares of drug-delivery technology specialist Catalent (NYSE: CTLT) jumped as much as 17% Tuesday morning in the wake of the company's 2017 fiscal year earnings report, released Monday after the market closed. As investors can probably guess, it was a pretty good 12 months. But management expects the next 12 months will be even better.
In addition to strong business momentum financially speaking, Catalent reported that it had entered into a long-term supply agreement to produce the next-generation OTC pain relief product from Pfizer, Advil Liqui-Gels Minis. It's just the latest indication that its growth won't be stopping anytime soon. As of 11:30 a.m. EDT, the stock had settled to a 15% gain.
Image source: Getty Images.
Source: Fool.com
Pfizer Inc. Aktie
26,27 €
-0,34 %
Die Community bevorzugt klar Pfizer Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Das Community-Kursziel von 41 € für Pfizer Inc. deutet auf eine deutliche Steigerung um mehr als 50% gegenüber dem aktuellen Kurs von 26.27 € hin.
